Neutrophil-Creatinine Index in Patients with Acute Pancreatitis: Assessment of Severity and Outcome

Launched by ASSIUT UNIVERSITY · Feb 13, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on a new way to assess the severity of acute pancreatitis (AP) in patients when they first arrive at the hospital. Acute pancreatitis is a condition where the pancreas becomes inflamed, and while most cases are mild, some can lead to serious complications that can be life-threatening. The trial is studying the "neutrophil-creatinine index" (NCI), a simple test that combines two lab results: the number of white blood cells called neutrophils and the level of creatinine in the blood. Higher levels of these markers may help doctors predict how severe a patient's condition might be right from the start, potentially leading to quicker and more effective treatment.

To participate in the trial, individuals must be at least 18 years old and diagnosed with acute pancreatitis. However, people with certain conditions, such as pancreatic cancer or chronic pancreatitis, or those who are pregnant, will not be eligible. Participants can expect to undergo the NCI test along with regular hospital care, which could help improve the understanding of acute pancreatitis and how to manage it better. This trial is not yet recruiting participants, but it aims to find a straightforward method for predicting the severity of this condition early on.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients with AP will be enrolled.
• • Both sexes
• • Age of patient \> 18 years old
• Exclusion Criteria:
• • Age less than 18 years old
• • Pancreatic cancer
• • Picture of chronic pancreatitis
• • Recurrent pancreatitis
• • pregnancy, end-stage renal disease, hematological disorders, pancreatic carcinoma or cholangiocarcinoma, and incomplete records.